OncoPeptTM is a powerful genomics platform to accelerate immuno-oncology research

MedGenome is the only Next Generation Sequencing (NGS) service provider offering immuno-oncology researchers an enduring, science-driven partnership to deliver quicker, more affordable and customized solutions. This enables superior therapeutic impact of checkpoint control inhibitors and cancer vaccines.

OncoPeptTM

An genomics platform for cancer immunotherapy companies
solutions
OncoPeptTUMETM
Provides immune phenotyping of the tumor microenvironment and analyses potenial biomarkers of response.
OncoPeptVACTM
Characterizes tumor mutanome to identify candidate vaccines
OncoPeptTCRTM
NGS based TCR repertoire analysis fordifferential diagnosis of T-cell related pathology
OncoPeptCOMBITM
Provides molecular rationale to combine therapies developed in the immuno-oncology space
OncoPeptTOPETM
A database of neo-antigens and neo-epitopes derived from genetic alterations available in TCGA data. Open access available at http://oncotope.medgenome.com
*To be launched soon
Benefits Value for the customer
Science driven Incorporates latest research insights to allow clients to use their time more efficiently and focus on their core research activities.
Customized solutions Allow seamless integration with clients ongoing research and caters to their specific preclinical and clinical research needs.
Quicker Turn Around Time at an affordable cost Robust and validated pipelines enable clients to complete their research in a shorter timeframe while minimizing the overall cost.
Partnership Supports clients need in creating presentation materials, figures for manuscripts and summary reports.
Accelerate your immuno-oncology research using OncoPeptTM

OncoPeptTUMETM

Provides immune phenotyping of the tumor microenvironment and analyses potenial biomarkers of response to enable success of checkpoint inhibitors.

Key benefits

  • Enables patient stratification for single agent or combination therapies
  • Enhances therapeutic benefit of checkpoint control inhibitors
  • Increases durability of response and patient outcome and aids in predicting adverse reaction to the drug

Biomarkers of response

diagram

Advantages of OncoPeptTUME TM over traditional approaches

Tumor microenvironment analysis

OncoPeptTUMETM Traditional (IHC/FACS-based)
Tissue type requirement
  • Requires less tissue material
  • FFPE or fresh frozen
  • All cell types can be analyzed from data
  • Requires more tissue material
  • FFPE or fresh frozen
  • Limiting cell types can be analyzed
Data generated
  • Information content high
  • Less variability in data
  • Quantitative (relative); spatial distribution not preserved
  • Information content low
  • High user to user variation
  • Quantitative (relative); spatial distribution preserved (IHC) but not for FACS
Effort, time and cost
  • Quicker Turn Around Time
  • Cost-effective
  • Labor and time intensive
  • Expensive per unit data generated on content low

OncoPeptVACTM

Delivers prioritized T-cell neo-epitopes, that can be used as DNA vaccine or peptide vaccine for cancer immunotherapy

Key benefits

  • Identify cancer variants with high specificity and sensitivity, cancer mutations that could be potentially HLA-binding and T-cell binding
  • Create optimum length of the DNA vaccine or peptide vaccine and ensure they are processed correctly to produce HLA-binding neo-epitope
  • Assay to determine efficient presentation of peptides by antigen presenting cells and ensure that these predicted peptide can activate
    T-cells

Selecting cancer vaccines from somatic mutations

OncoPeptVACTM uses multiple filters to eliminate greater than 99% of neo-antigens to select true T-cell neo-epitopes

>2-log enrichment in
neo-epitope prioritization

Advantages of OncoPeptVAC TM over traditional approaches

Tumor neo-epitope analysis

OncoPeptVACTM Traditional (Cell-based)
Pre-clinical studies
  • Any tumor model can be used
  • Scalable
  • Quicker Turn Around Time and cost effective
  • Requires specific animal models
  • Not scalable
  • Time consuming and expensive
Clinical studies
  • Cancer vaccines can be discovered from exome and RNA-seq data
  • Standard NGS pipeline
  • Scalable
  • Quicker Turn Around Time and cost effective
  • Requires manipulation of immune cells from the patient
  • Highly specialized assays
  • Not scalable
  • Time consuming and expensive

OncoPeptTOPE TM

Delivers prioritized T-cell neo-epitopes, that can be used as DNA or peptide vaccine for cancer immunotherapy

The database captures CD4+/CD8+ T-cell neo-epitopes from neo-antigens based on their binding affinity to different HLA types and selected based on their expression in cancer cells. Mutated genes are rank ordered according to their T-cell neo-epitope burden.

The analysis provides an explanation as to why T-cell neo-epitopes are largely private and not shared between samples.

OncoPeptTOPETM web interface allows visualization of neo-epitopes across genes and cancers. Data is accessed by Gene/Transcript ID and/or variant information. Data can be filtered further on HLA type and prevalence of the mutant epitope across different cancers

Click below to get free access
OncoPeptTOPE TM database
Sitemap